AHA 2025 — In this interview, Dr Narendra Singh (NSC Cardiology, Atlanta, US) reviews the latest AHA data on etripamil, an investigational intranasal, nondihydropyridine calcium channel blocker for the rapid self-termination of paroxysmal supraventricular tachycardia (PSVT).

Dr Singh discusses the burden of PSVT, key findings from randomized and open-label studies, conversion rates with single and repeat dosing, safety and tolerability, and the potential for at-home, patient-administered therapy to reduce emergency department utilization. Dr Singh also addresses considerations around misdiagnosis, hemodynamic effects, and how etripamil could integrate into future PSVT management strategies, including its role alongside ablation.

Interview Questions: 
What is etripamil, and what is its therapeutic purpose?
Which clinical studies were included in the AHA analysis?
What were the key safety and efficacy findings?
What side effects were observed in the studies?
How does PSVT impact patients and the healthcare system?
Why is self-administered treatment important in managing PSVT?
What are the current standards of care for PSVT, and what unmet needs remain?

Recorded on-site at AHA 2025.